Australia's most trusted
source of pharma news
Saturday, 02 August 2025
Posted 29 July 2025 AM
Novo Nordisk has lost a patent infringement lawsuit against Viatris subsidiary Mylan over its plans to launch a generic version of Wegovy.
The patent in question is in the US, and covers the administration of semaglutide without another therapeutic agent for the purposes of weight loss. Novo claimed that by launching the competing product Mylan would induce others to infringe the patent.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.